HeyHippocratesDiabetes, pneumonia, hypertension — a colleague who cites every call.
Clinical decision support that reasons like an internist while you decide: individualize the target, choose the organ-protective agent, risk-stratify the disposition — with the decision rule and exactly what would change it. Built for verified internists.
Watch it think — in internal medicine.
Two worked examples, reasoned the way it answers: the relevant clinical checks run, the answer is cited, the decision rule is explicit, and what is missing is flagged.
58-year-old with type-2 diabetes, HbA1c 8.5%, established ASCVD and CKD, already on metformin — which agent next?
With established ASCVD and CKD, the next agent is chosen for organ protection, not just glucose. An SGLT2 inhibitor is preferred here — it slows CKD progression and reduces heart-failure and cardiovascular events, independent of the HbA1c. A GLP-1 receptor agonist is the alternative or add-on with strong cardiovascular benefit and weight loss. Continue metformin and lifestyle, and titrate to an individualized target.
Decision ruleT2DM + ASCVD/CKD/HF → add an SGLT2 inhibitor (or GLP-1 RA) for organ protection regardless of HbA1c; keep metformin; individualize the glycemic target.
Not established from this alone — eGFR, heart-failure status, weight, hypoglycemia risk and cost change the choice.
72-year-old, productive cough and fever, new confusion, respiratory rate 24, blood pressure 100/60, urea elevated — CURB-65 and disposition?
Score CURB-65: confusion (1), a raised urea (1), and age ≥65 (1) give at least 3 — a high-risk community-acquired pneumonia. That supports hospital admission with consideration of higher-level care, blood cultures, and prompt empirical antibiotics per local guidance. Reassess the respiratory rate and blood pressure, which can push toward critical care.
Decision ruleCURB-65 0–1 → outpatient; 2 → consider admission; ≥3 → admit and consider critical care; start prompt empirical antibiotics.
Not established from this alone — oxygenation, the exact vitals, comorbidity and social support change the disposition.
Illustrative simulations. The physician always decides.
The answers internists actually look up.
The exact questions your field searches for — answered in the format the knowledge base speaks: the answer, the decision rule, what's missing, and the source.
Type-2 diabetes — glycemic target and choosing the agent?
Individualize the HbA1c target — around 7% for many, tighter in the young and healthy, looser in the frail or those at hypoglycemia risk. Metformin and lifestyle are foundational, but the second agent is chosen by comorbidity: an SGLT2 inhibitor or GLP-1 receptor agonist for established ASCVD, heart failure or CKD (independent of HbA1c), a GLP-1 RA when weight matters, and cost and hypoglycemia risk always weighed.ADA/EASD · guideline
Decision ruleIndividualize HbA1c (~7%); metformin + lifestyle; comorbidity-driven second agent (SGLT2i/GLP-1 RA for ASCVD/HF/CKD, regardless of HbA1c).
Missing data: eGFR, heart failure, weight, hypoglycemia risk and cost change the agent and the target.
Community-acquired pneumonia — CURB-65 and disposition?
CURB-65 scores Confusion, Urea over 7 mmol/L, Respiratory rate ≥30, low Blood pressure (SBP under 90 or DBP 60 or less) and age ≥65, one point each. A score of 0–1 usually allows outpatient care, 2 warrants consideration of admission, and 3–5 means admit with consideration of critical care. Pair it with oxygenation and clinical judgment, and start prompt empirical antibiotics.CURB-65
Decision ruleCURB-65 0–1 → outpatient; 2 → consider admission; 3–5 → admit ± critical care; add oxygenation and judgment; do not delay antibiotics.
Missing data: oxygen saturation, comorbidity, the exact vitals and social factors refine the disposition.
Hypertension — the target and first-line agents?
Confirm hypertension with out-of-office readings before committing to lifelong therapy. The target is generally below 130/80 for most adults. Start lifestyle change, and choose a first-line agent from a thiazide-type diuretic, an ACE inhibitor or ARB, or a calcium-channel blocker; stage-2 hypertension usually needs two agents from the start. Match the choice to comorbidity — an ACEi/ARB in diabetes or CKD.ACC/AHA · guideline
Decision ruleConfirm out-of-office; target <130/80 for most; first-line thiazide/ACEi-ARB/CCB; stage 2 → two agents; match to comorbidity.
Missing data: the confirmed readings, comorbidity, age and secondary causes change the target and the agent.
Iron-deficiency anemia — the workup?
A microcytic anemia with a low ferritin is iron deficiency. The task is not just to replace iron but to find the source: in men and postmenopausal women, evaluate for gastrointestinal blood loss with upper and lower endoscopy; in menstruating women, weigh menstrual and dietary causes but still investigate alarm features. Replace iron orally or intravenously, and recheck the response.guideline synthesis
Decision ruleMicrocytic + low ferritin → iron deficiency; find the source (GI evaluation in men/postmenopausal women); replace iron and confirm the response.
Missing data: the ferritin, red-cell indices, symptoms and alarm features drive the investigation.
What it knows in internal medicine
Your whole practice, one specialist brain — grounded in specialist-written, cited knowledge.
A generalist internist colleague across diabetes, cardiovascular, respiratory, renal and the diagnostic workup — cited, non-directive, always with the decision rule.
Deep specialist agents for endocrinology, cardiology, pulmonology, nephrology and infectious diseases — each its own specialist voice and knowledge base — plus your own uploaded materials.
Why not just use OpenEvidence or ChatGPT?
A large language model answers any clinical question with total confidence and no idea whether it is right. A search engine finds papers. HeyHippocrates reasons inside your specialty from a knowledge base a specialist in your field wrote and signed, and tells you the decision rule and what is missing.
Be one of the first internists in.
The waitlist is a founding cohort: 40 specialties in build, neurosurgery opens first, and your specialty’s waitlist decides what opens next.
- 1 free month — the whole product, no card.
- Then 50% off for three months.
- A numbered Founding Internist badge.
- First say on what your specialty gets next.
Join the internal medicine waitlist
Leave your name and work email. We'll reach out the moment internal medicine opens — with your Founding Internist offer.
One email at launch. No spam, ever.
Questions internists ask
It reasons in the tools you use — the individualized HbA1c target, CURB-65 and cardiovascular risk — and always shows the reasoning, the decision rule and what would change it. The decision always stays your call.
Both. Residents use it to pressure-test a plan and learn the decision rule; attendings use it as a fast, cited second opinion on rounds and in clinic. Access is gated to verified physicians.
The main internal-medicine sub-specialties — endocrinology, cardiology, pulmonology, nephrology and infectious diseases — each have their own deep specialist agent on the Pro plan, on top of the full general-internal-medicine scope on Basic.
No. It is physician-facing clinical decision support — a cited thinking partner. It does not diagnose, does not treat, and gives no patient-facing advice. The decision always stays with you.
Every answer is grounded only in specialist-written, cited internal-medicine knowledge — traceable to a named source — and always states the decision rule plus what data is missing, instead of a confident guess.